Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > NVS Novartis AG > Detailed Quotes

NVS Novartis AG

Watchlist
85.820
+0.440+0.52%
Close 08/16 16:00 ET
85.82000.00%
Post Mkt Price 08/16 16:10 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
85.840
Open
84.920
Turnover
141.22M
Low
84.850
Pre Close
85.380
Volume
1.65M
Market Cap
187.33B
P/E(TTM)
8.41
52wk High
94.260
Shares
2.18B
P/E(Static)
8.07
52wk Low
76.151
Float Cap
184.52B
Bid/Ask %
0.00%
Historical High
94.260
Shs Float
2.15B
Volume Ratio
0.82
Historical Low
13.499
Dividend TTM
3.325
Div Yield TTM
2400
P/B
2.98
Dividend LFY
3.87%
Div Yield LFY
2796.55%
Turnover Ratio
0.08%
Amplitude
1.16%
Avg Price
85.391
Lot Size
1
Float Cap
184.52B
Bid/Ask %
0.00%
Historical High
94.260
Shs Float
2.15B
Volume Ratio
0.82
Historical Low
13.499
Dividend TTM
3.325
P/B
2.98
Dividend LFY
3.87%
Turnover Ratio
0.08%
Amplitude
1.16%
Avg Price
85.391
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
CEO: Birch, Neil William
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top